Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
137 participants
OBSERVATIONAL
2014-03-31
2018-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Swiss Rare Disease Registry (SRDR)
NCT05179863
Rhythm Disturbances After Ventricular Septal Defects
NCT00208624
Cerebral Blood Flow in Single Ventricles Throughout Staged Surgical Reconstruction
NCT02135081
Evaluation of A Clinical Diagnostic Test for CRDS
NCT06188689
Early Diagnosis Of Childhood Cerebral ALD
NCT02948062
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Cerebral Palsy is an all-encompassing term for numerous neurological conditions caused by problems in the brain and nervous system. More specifically, cerebral palsy is related to problems in muscle movement, which result in abnormalities in walking, posture, and balance. Other important functions can also be affected, such as language/communication, learning, and vision. There is currently no cure for cerebral palsy; however, there are several treatment options that can aid alleviation of symptoms and improve quality of life. The selection of appropriate treatment(s) for each child requires input from a multi-disciplinary team of health professionals, such as paediatricians, social workers, physiotherapists, speech and language therapists, occupational therapists, neurologists and surgeons.
Treatment overview:
The National Institute for Health and Care Excellence (NICE) published guidance related to treatment options for cerebral palsy in 2012 (CG145). One of the treatment options discussed was Selective Dorsal Rhizotomy (SDR). SDR is an irreversible surgical procedure, which involves the division of some of the sensory nerves of the spinal cord in order to reduce sensory input to the sensory-motor reflex arcs. Intensive physiotherapy is required SDR post surgery for up to 24 months to achieve the outcome goals of improvement in muscle function, tone, and quality of life. NICE CG145 recommends consideration of SDR in children with a GMFCS level II or III. This recommendation was based on a review of evidence evaluation, which concluded that there was reasonable evidence that SDR combined with appropriate post-operative treatment can result in significant improvements in motor function and quality of life.
Study Overview:
This current project is being commissioned by NICE to support NHS England in its Commissioning through Evaluation (CTE) approach. CTE was launched in September 2013 and involves funding medical treatments and technologies not routinely commissioned within the NHS. SDR is one such procedure which was selected for CTE, with the aim of evaluating the 'outcome of SDR and demonstrate improvement in function after SDR at 6 months that is maintained or improved at 12 months and two years post operation'. As part of this programme, NICE commissioned, in early 2014, a data collection and register development service from one of its External Assessment Centres (EACs): King's Imaging Technology Evaluation Centre (KiTEC). The key objective of the KiTEC EAC is to collect SDR related data that will inform clinical effectiveness and other outcomes of interest to NHS England in making its commissioning plans and addressing the following research question from section 4.5 of CG145:
'Does selective dorsal rhizotomy followed by intensive rehabilitation performed between the ages of 3 and 9 years in children who are at GMFCS level II or III result in good community mobility as a young adult?'
Study Design:
This is a multi-centre national database (register) project to obtain the evidence related to SDR that will address the research question in section 4.5 of CG145 and inform clinical effectiveness and other outcomes of interest to NHS England. All patients will undergo pre-assessment prior to undergoing SDR. This varies between centres, and can be anywhere from 6 months prior to SDR. Hospital admission for SDR usually is between 1-2 weeks. Post-SDR follow-up will be conducted up to two years for the purposes of this project. All patients' will followed up to two years post-SDR by members of the relevant clinical team. Post-SDR discharge there will be three main data collection points for the purposes of this project: 6, 12 and 24 months post-SDR. Patient data will be collected at various time-points, as agreed between the EAC and various SDR subgroup members. Pre-assessments may be split into more than one appointment, depending on the particular patient care pathway at each participating centre.
Parents of patients will be approached by the SDR clinical team when they attend for their first pre-SDR clinic visit. It will be explained to the parents and children that their hospital will be making clinical assessments before and after SDR to enable them to provide optimum care and to evaluate the success of the operation and post-operative rehabilitation. These assessments along with patient-reported outcomes, such as quality of life assessments, will be standardised across all five commissioned hospitals. The parents and children will be asked for permission to add their data to the national database to facilitate aggregation of results across the United Kingdom (UK).
Study information sheets will be provided. If they agree to take part, parents will sign a consent form at the 2nd pre-SDR visit. This will allow time for them to consider whether or not they wish to take part.
Centre and Subject Compliance:
Centre compliance refers to all centres providing the agreed standardised dataset and input into the standardised database as per the CTE selection criteria. The EAC will regularly monitor Centre compliance in liaison with NHS England and include tables of compliance in the project report. The project report (with potential for interim analysis) will include tables on the number of eligible patients that were referred for treatment through the multi-disciplinary team process and consented to part of the database as well as those that were actually registered in the SDR database. The project report (with potential for interim analysis) will list the percentage of missing data in each of the clinical domains and differentiate between baseline and follow-up variables. Depending on the stage of the database a table depicting the number of children that have been lost to follow up will be included in the project report or in potential interim analyses reports. The SDR centres will be given regular reports on the quality of their data in terms of missing variables and possible outliers.
Statistical Considerations:
The EAC statisticians will carry out all analyses. All data obtained will be analysed at regular specified time points to inform ongoing assessment of the clinical effectiveness, relevant outcomes and assessment of the overall research question.The SDR database is expected to have small numbers, in the region of up to n=120 a year in England. A range of clinical and patient-reported outcomes will be recorded and there will be no single primary or secondary outcome. Rather the aim is to describe and quantify the changes in a number of important clinical domains such as spasticity, function, range of motion, gait and quality of life.
Ethical Considerations:
As the database constitutes research involving human subjects, the following ethical considerations arise:
* Parental consent will be required to add the child's data to the national database and patient information sheets (PIS) have been developed for both children and parents of potential children at the designated SDR centres.
* Only the minimum number of data items needed to meet the objectives of the database and comply with ethical and regulatory requirements will be included in the final dataset.
* Children's confidentiality will be protected during data collection and handling thus reducing the risk of disclosure.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
These will be asked to consent to their outcome data being added to the national database. There are no exclusions to the database.
For inclusion in the CTE SDR programme, the criteria were established as:
* Children between the ages of 3 and 9 years with a diagnosis of spastic diplegic cerebral palsy (based on NICE guidance \[2\]).
* Dynamic spasticity in lower limbs affecting function and mobility and no dystonia
* MRI shows typical Cerebral palsy changes and no damage to key areas of brain controlling posture and coordination.
* GMFCS level II or III.
* No evidence of genetic or neurological progressive illness.
* Mild to moderate lower limb weakness with ability to maintain antigravity postures.
* No significant scoliosis or hip dislocation (Reimer's index \[10\] should be \<40%).
* In addition to the above clinical criteria there must be written agreement from the referring responsible commissioner confirming financial and resource commitment to provide the post operative physiotherapy package as outlined in the CTE SDR programme selection criteria \[5\].
Exclusion Criteria
* Gross Motor Function Classification System levels I, IV or V.
3 Years
9 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
King's College London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janet Peacock, PhD
Role: PRINCIPAL_INVESTIGATOR
King's College London, London, United Kingdom
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
162253
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.